WCM Investment Management LLC Reduces Holdings in ICU Medical, Inc. $ICUI

WCM Investment Management LLC lowered its position in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 1.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 236,623 shares of the medical instruments supplier’s stock after selling 2,761 shares during the period. WCM Investment Management LLC owned approximately 0.96% of ICU Medical worth $31,192,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the company. Allianz Asset Management GmbH acquired a new stake in shares of ICU Medical during the second quarter worth approximately $4,296,000. Bayforest Capital Ltd acquired a new stake in shares of ICU Medical during the second quarter worth approximately $257,000. Equitable Trust Co. grew its position in shares of ICU Medical by 59.8% during the second quarter. Equitable Trust Co. now owns 8,538 shares of the medical instruments supplier’s stock worth $1,128,000 after buying an additional 3,196 shares in the last quarter. Verdence Capital Advisors LLC acquired a new stake in shares of ICU Medical during the second quarter worth approximately $484,000. Finally, Johnson Investment Counsel Inc. grew its position in shares of ICU Medical by 17.7% during the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 256 shares in the last quarter. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Insider Transactions at ICU Medical

In related news, Director David C. Greenberg acquired 1,200 shares of the business’s stock in a transaction that occurred on Wednesday, August 27th. The shares were acquired at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the completion of the purchase, the director directly owned 7,960 shares in the company, valued at $1,006,303.20. This trade represents a 17.75% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Vivek Jain acquired 21,929 shares of the business’s stock in a transaction that occurred on Thursday, August 14th. The shares were bought at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the completion of the purchase, the chief executive officer owned 130,149 shares of the company’s stock, valued at approximately $14,686,013.16. This represents a 20.26% increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.50% of the stock is owned by insiders.

ICU Medical Stock Performance

ICU Medical stock opened at $116.29 on Thursday. The company has a market cap of $2.87 billion, a PE ratio of -76.51 and a beta of 0.83. The company has a fifty day moving average price of $123.61 and a two-hundred day moving average price of $130.35. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17. ICU Medical, Inc. has a 12 month low of $107.00 and a 12 month high of $196.26.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. During the same quarter in the previous year, the company posted $1.56 earnings per share. The company’s revenue for the quarter was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Research analysts expect that ICU Medical, Inc. will post 4.11 earnings per share for the current year.

Wall Street Analyst Weigh In

ICUI has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Friday, September 5th. Raymond James Financial decreased their price target on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating for the company in a research report on Friday, August 8th. Piper Sandler raised their price target on shares of ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $181.00.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.